NEW YORK (360Dx) – Abionic said today that it closed a CHF20 million ($21.1 million) Series C financing round for use in extending its portfolio of point-of-care IVD tests for critical care and emergency medicine.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.